SENZA logo

SenzaGen AB Stock Price

OM:SENZA Community·SEK 169.4m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

SENZA Share Price Performance

SEK 5.74
-1.76 (-23.47%)
SEK 5.74
-1.76 (-23.47%)
Price SEK 5.74

SENZA Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet and slightly overvalued.

1 Risk
1 Reward

SenzaGen AB Key Details

SEK 57.9m

Revenue

SEK 20.2m

Cost of Revenue

SEK 37.7m

Gross Profit

SEK 53.9m

Other Expenses

-SEK 16.2m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 13, 2026
-0.55
65.09%
-27.95%
7.6%
View Full Analysis

About SENZA

Founded
2010
Employees
37
CEO
Peter Nahlstedt
WebsiteView website
senzagen.com

SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices. In addition, the company offers regulatory toxicity testing services, including skin corrosion, skin irritation, skin sensitization, and skin absorption; and eye irritation, phototoxicity, and genotoxicity testing services. Further, it provides advisory services, such as pharma, medical devices, cosmetics, and chemical. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. SenzaGen AB was incorporated in 2010 and is headquartered in Lund, Sweden.

Recent SENZA News & Updates

Recent updates

No updates